Skip to main content
MedPathMedPath Home
Clinical Trials/PER-004-02
PER-004-02
Unknown
Phase 1

THE EFFECTIVENESS AND SAFETY OF AN INDIVIDUALISED SYMBICORTÒ TURBUHALERÒ MAINTENANCE DOSING REGIMEN (SYMBICORTÒ ASTHMA CONTROL PLAN) VERSUS SYMBICORTÒ TURBUHALERÒ GIVEN AS STANDARD REGULAR TWICE DAILY THERAPY. THE SYMBICORT ADJUSTABLE MAINTENANCE STUDY (SAM)

ASTRAZENECA - PERU,0 sites0 target enrollmentJanuary 7, 2002
Share to TwitterShare to FacebookShare to LinkedInShare to Reddit
Conditions-J459 Asthma, unspecifiedAsthma, unspecifiedJ459

Overview

Phase
Phase 1
Intervention
Not specified
Conditions
-J459 Asthma, unspecified
Sponsor
ASTRAZENECA - PERU,
Last Updated
2 years ago
OverviewInvestigatorsEligibility CriteriaOutcomesSimilar Trials

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
January 7, 2002
End Date
TBD
Last Updated
2 years ago
Study Type
Interventional

Investigators

Sponsor
ASTRAZENECA - PERU,

Eligibility Criteria

Inclusion Criteria

  • •Patients currently well managed with inhaled corticosteroids and long\-acting bronchodilators, or patients currently controlled with inhaled corticosteroids and short\-acting bronchodilators, who present a level of symptoms indicating the need to use additional therapy, in accordance with the guidelines of the National Institute of Heart, Lung and Blood (NHLBI) for the management of asthma.

Exclusion Criteria

  • •1\) FEP \<50% of predicted (if measured)
  • •2\) Patients with regular daily treatment with:\> 2,000 mcg of beclomethasone dlpropionate (BDP) or fluticasone propionate or\> 1,600 mcg of budesonide
  • •3\) Current requirements for oral steroids or use of oral steroids\> 10 days in the previous 3 months.
  • •4\) Current use of any p\-blocking therapy (including eye drops).
  • •5\) Infections of the upper respiratory tract in the previous four weeks.
  • •6\) Severe cardiovascular disease or any other significant concomitant disease that may interfere with the conduct of the study
  • •7\) Known or suspected hypersensitivity to budesonide, formoterol or inhaled lactose.
  • •8\) Pregnancy, planned pregnancy or breastfeeding.

Outcomes

Primary Outcomes

Not specified

Similar Trials

Completed
Not Applicable
Feasibility and effectiveness of an individualized, group-based physical exercise program with educational components in people with knee and/or hip OA – a randomized controlled pilot studyPersons with hip and/or knee (osteo)arthrosis, which has been diagnosed by a physician. In addition, the criteria of the American College of Rheumatology” for an idiopathic arthrosis of the hip joint (Altman et al., 1991) or an arthrosis of the knee joint (Altman et al., 1986) should be fulfilled.M15M16M17PolyarthrosisCoxarthrosis [arthrosis of hip]Gonarthrosis [arthrosis of knee]
DRKS00018847Hochschule für Gesundheit, Bochum52
Recruiting
Not Applicable
Evaluating the effectiveness of an individualized monitoring and education system and related services for the optimal patient care of chronic diseases in primary clinics
KCT0008396The Catholic University of Korea1,000
Completed
Not Applicable
Which Potencies of Homeopathy acts well for Osteoarthritis
CTRI/2023/01/049219Dr S Stevenson30
Not yet recruiting
Not Applicable
Efficacy of individualized internet-based physical activity intervention in increasing physical activity.
IRCT20180129038545N1Tehran University of Medical Sciences152
Completed
Phase 4
survey to examine the acceptability of the product Vitazyme Drops in young child to manage severe pain in the abdomen caused by wind or obstruction in the intestine characterized by high pitch crying, restlessnessHealth Condition 1: K598- Other specified functional intestinal disorders
CTRI/2019/04/018561East India Pharmaceutical Works Limited200